Summarized by Masters of Longevity from Longevity Technology.
A news article about early clinical progress for a novel long‑acting Parkinson’s therapy, previewing safety review results and initial blinded signals.
Key Takeaways
- An independent Safety Monitoring Committee cleared Cohort 1 to proceed to a higher dose in the Phase 1b trial.
- Cohort 1 (eight patients) showed sustained apomorphine exposure consistent with a long-acting delivery profile.
- Exploratory blinded observations reported sustained periods of improved motor function in individual treated patients.
